ecancermedicalscience

Review

Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door

17 Jan 2022
Mauro Daniel Spina Donadio, Dirce Maria Carraro, Giovana Tardin Torrezan, Celso Abdon Lopes de Mello

Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) genes is gaining importance as predictors of fluoropyrimidine-associated toxicity. The recommendation of dose adjustment for chemotherapy guided by the presence of polymorphisms of the DPYD gene can potentially improve treatment safety for a large number of patients, saving lives, avoiding complications and reducing health care costs. This article discusses how personalisation of fluoropyrimidine treatment based on the identification of DPYD variants can mitigate toxicities and be cost effective.

Related Articles

Goutam Santosh Panda, Vanita Noronha, Subhash Yadav, Amit Joshi, Vijay Patil, Nandini Menon, Rajiv Kumar, Amit Janu, Abhishek Mahajan, Nilendu Purandare, Jai Prakash Agarwal, George Karimundackal, Kumar Prabhash
Goutam Santosh Panda, Vanita Noronha, Darshit Shah, George John, Anuradha Chougule, Vijay Patil, Rajiv Kumar, Nandini Menon, Ajay Singh, Pratik Chandrani, Abhishek Mahajan, Kumar Prabhash
Rahat Ul-Ain, Mahwish Faizan, Saadia Anwar, Shazia Riaz, Alia Ahmad, Huma Zafar, Wasila Shamim
Anant Ramaswamy, Sujay Srinivas, Vikram Chaudhari, Prabhat Bhargava, Manish Bhandare, Shailesh V Shrikhande, Vikas Ostwal